Neoadjuvant Chemotherapy First, Followed by Chemoradiation and Then Surgery, in the Management of Locally Advanced Rectal Cancer

View More View Less
  • a From the Gastrointestinal Oncology Service, Department of Medicine, Department of Radiation Therapy, and Colorectal Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York.
Restricted access

Standard therapy for locally advanced rectal cancer (LARC) is preoperative chemoradiotherapy and postoperative chemotherapy. At Memorial Sloan-Kettering Cancer Center (MSKCC) the authors began offering FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) as initial treatment for patients with high-risk LARC to target micrometastases while treating the primary tumor. The purpose of this study is to report the safety and efficacy of initial FOLFOX given before chemoradiotherapy on tumor downsizing and pathologic complete response (pathCR) in LARC. The records of patients with stage II/III rectal cancer treated at MSKCC between 2007 and 2012 were reviewed. Of approximately 300 patients with LARC treated at MSKCC, 61 received FOLFOX as initial therapy. Of these 61 patients, 57 received induction FOLFOX (median 7 cycles) followed by chemoradiation, and 4 experienced an excellent response, declined chemoradiation, and underwent total mesorectal excision (TME). Twelve of the 61 patients did not undergo TME: 9 had a complete clinical response (CCR), 1 declined despite persistent tumor, 1 declined because of comorbidities, and 1 developed metastatic disease. Among the 61 patients receiving initial FOLFOX, 22 (36%) had either a pathCR (n=13) or a CCR (n=9). Of the 49 patients who underwent TME, all had R0 resections and 23 (47%) had tumor response greater than 90%, including 13 (27%) who experienced a pathCR. Of the 28 patients who received all 8 cycles of FOLFOX, 8 experienced a pathCR (29%) and 3 a CCR (11%). No serious adverse events occurred that required a delay in treatment during FOLFOX or chemoradiation. FOLFOX and chemoradiation before planned TME results in tumor regression, a high rate of delivery of planned therapy, and a substantial rate of pathCRs, and offers a good platform for nonoperative management in select patients.

Correspondence: Andrea Cercek, MD, Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, New York, NY 10065. E-mail: cerceka@mskcc.org
  • 1.

    NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:14441450.

  • 2.

    Sauer R, Becker H, Hohenberger W. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:17311740.

  • 3.

    Fisher B, Wolmark N, Rockette H. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:2129.

    • Search Google Scholar
    • Export Citation
  • 4.

    Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985;312:14651472.

    • Search Google Scholar
    • Export Citation
  • 5.

    Goldberg RM, Sargent DJ, Morton RF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:2330.

    • Search Google Scholar
    • Export Citation
  • 6.

    Grothey A, Sargent D, Goldberg RM. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:12091214.

    • Search Google Scholar
    • Export Citation
  • 7.

    Andre T, Boni C, Mounedji-Boudiaf L. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:23432351.

    • Search Google Scholar
    • Export Citation
  • 8.

    de Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:29382947.

    • Search Google Scholar
    • Export Citation
  • 9.

    Cercek A, Weiser M, Goodman KA. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 3649

    • Search Google Scholar
    • Export Citation
  • 10.

    Schrag D, Weiser MR, Goodman KA. Neoadjuvant FOLFOX-bev without radiation, for locally advanced rectal cancer [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 3511.

    • Search Google Scholar
    • Export Citation
  • 11.

    Chau I, Brown G, Cunningham D. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668674.

    • Search Google Scholar
    • Export Citation
  • 12.

    Fernandez-Martos C, Pericay C, Aparicio J. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J Clin Oncol 2010;28:859865.

    • Search Google Scholar
    • Export Citation
  • 13.

    Haller DG, Tabernero J, Maroun J. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:14651471.

    • Search Google Scholar
    • Export Citation
  • 14.

    Yothers G, O’Connell MJ, Allegra CJ. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:37683774.

    • Search Google Scholar
    • Export Citation
  • 15.

    Washington MK, Berlin J, Branton LJ. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 2009;133:15391551.

    • Search Google Scholar
    • Export Citation
  • 16.

    Sinicrope F, Mahoney MR, Smyrk TC. Prognositic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013;31:36643672.

    • Search Google Scholar
    • Export Citation
  • 17.

    Hugen N, Verhoevem RH, Lemmens VE. Colorectal signet-ring cell carcinoma: responsive to adjuvant chemotherapy but still a poor prognosis [abstract]. J Clin Oncol 2014;32(Suppl 3):Abstract 529.

    • Search Google Scholar
    • Export Citation
  • 18.

    Chua YJ, Barbachano Y, Cunningham D. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010;11:241248.

    • Search Google Scholar
    • Export Citation
  • 19.

    Gerard JP, Conroy T, Bonnetain F. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:46204635.

    • Search Google Scholar
    • Export Citation
  • 20.

    Bosset JF, Collette L, Calais G. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:11141123.

  • 21.

    Land SR, Ritter MW, Costantino JP. Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. J Clin Oncol 2007;25:51135120.

    • Search Google Scholar
    • Export Citation
  • 22.

    Goldberg PA, Nicholls RJ, Porter NH. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure. Eur J Cancer 1994;30A:16021606.

    • Search Google Scholar
    • Export Citation
  • 23.

    van Gijn W, Marijnen CA, Nagtegaal ID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575582.

    • Search Google Scholar
    • Export Citation
  • 24.

    Hatfield P, Hingorani M, Radhakrishna G. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009;92:210214.

    • Search Google Scholar
    • Export Citation
  • 25.

    Maas M, Nelemans PJ, Valentini V. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835844.

    • Search Google Scholar
    • Export Citation
  • 26.

    Capirci C, Valentini V, Cionini L. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008;72:99107.

    • Search Google Scholar
    • Export Citation
  • 27.

    Chang GJ, Rodriguez-Bigas MA, Eng C. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer 2009;115:54325440.

    • Search Google Scholar
    • Export Citation
  • 28.

    Das P, Skibber JM, Rodriguez-Bigas MA. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol 2006;29:219224.

    • Search Google Scholar
    • Export Citation
  • 29.

    Kuo LJ, Liu MC, Jian JJ. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 2007;14:27662772.

    • Search Google Scholar
    • Export Citation
  • 30.

    Quah HM, Chou JF, Gonen M. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008;113:5764.

    • Search Google Scholar
    • Export Citation
  • 31.

    Stipa F, Chessin DB, Shia J. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol 2006;13:10471053.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 608 281 35
PDF Downloads 215 126 16
EPUB Downloads 0 0 0